Sprucegrove Investment Management Ltd. Sells 26,700 Shares of Becton, Dickinson and Company (NYSE:BDX)

Sprucegrove Investment Management Ltd. reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 15.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 150,600 shares of the medical instruments supplier’s stock after selling 26,700 shares during the quarter. Sprucegrove Investment Management Ltd.’s holdings in Becton, Dickinson and were worth $36,618,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC increased its holdings in Becton, Dickinson and by 8.4% in the 1st quarter. Los Angeles Capital Management LLC now owns 5,986 shares of the medical instruments supplier’s stock valued at $1,455,000 after buying an additional 462 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Becton, Dickinson and by 1.0% during the 4th quarter. New York State Common Retirement Fund now owns 929,443 shares of the medical instruments supplier’s stock valued at $232,565,000 after purchasing an additional 9,615 shares during the last quarter. Gamco Investors INC. ET AL grew its holdings in shares of Becton, Dickinson and by 4.3% during the 4th quarter. Gamco Investors INC. ET AL now owns 46,674 shares of the medical instruments supplier’s stock valued at $11,679,000 after purchasing an additional 1,945 shares during the last quarter. Mcrae Capital Management Inc. grew its holdings in shares of Becton, Dickinson and by 28.1% during the 1st quarter. Mcrae Capital Management Inc. now owns 19,307 shares of the medical instruments supplier’s stock valued at $4,694,000 after purchasing an additional 4,235 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Becton, Dickinson and by 4.7% during the 1st quarter. Treasurer of the State of North Carolina now owns 126,426 shares of the medical instruments supplier’s stock valued at $30,740,000 after purchasing an additional 5,620 shares during the last quarter. 83.51% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on BDX shares. SVB Leerink cut their target price on shares of Becton, Dickinson and from $270.00 to $260.00 and set a “market perform” rating on the stock in a research report on Friday, May 7th. Barclays began coverage on shares of Becton, Dickinson and in a research report on Monday, May 24th. They set an “equal weight” rating and a $270.00 target price on the stock. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $276.67.

In other news, Director Claire Fraser sold 390 shares of the company’s stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $241.36, for a total value of $94,130.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.76% of the company’s stock.

BDX stock traded down $1.31 during midday trading on Friday, reaching $244.10. 4,533 shares of the company’s stock traded hands, compared to its average volume of 1,374,115. The firm has a market capitalization of $70.99 billion, a P/E ratio of 43.67, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm has a fifty day simple moving average of $246.81. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.32 and a current ratio of 1.86. Becton, Dickinson and Company has a 52 week low of $219.50 and a 52 week high of $284.97.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Wednesday, May 5th. The medical instruments supplier reported $3.19 EPS for the quarter, beating the Zacks’ consensus estimate of $3.04 by $0.15. Becton, Dickinson and had a net margin of 8.98% and a return on equity of 15.53%. The business had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.88 billion. During the same quarter in the previous year, the business posted $2.55 EPS. Becton, Dickinson and’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.81 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 30th. Stockholders of record on Wednesday, June 9th will be paid a $0.83 dividend. The ex-dividend date is Tuesday, June 8th. This represents a $3.32 annualized dividend and a dividend yield of 1.36%. Becton, Dickinson and’s payout ratio is 32.55%.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What’s a Black Swan?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.